Cytomegalovirus antigenemia and outcomes of patiens undergoing allogeneic peripheral blood stem cell transplantation: Effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment

Japanese Journal of Infectious Diseases

Volumn 59, Issue 4, 2006, Pages 216-221

  Hazar, Volkan ^a   Ugur, Aynur ^a   Colak, Dilek ^a   Saba, Rabin ^a   Tezcan, Gulsun ^a   Kupesiz, Alphan ^a   Karadogan, Ihsan ^a   Gultekin, Meral ^a   Yesilipek, Akif ^a   Undar, Levent ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALBERS SCHOENBERG DISEASE; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CHEDIAK HIGASHI SYNDROME; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG MEGADOSE; FANCONI ANEMIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMOGLOBINOPATHY; HUMAN; INCIDENCE; INFANT; INFECTION RISK; JUVENILE MYELOMONOCYTIC LEUKEMIA; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPHIL; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INFANT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748121126     PISSN: 13446304     EISSN: 13446304     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (2000): Guidelines for preventing opportunistic infections among hematopoietic stem cell transplantation recipients: recommendation of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Morbid. Motal. Wkly. Rep., 49 (RR-10), 15-16.
2. Meyers, J. D., Reed, E. C., Shepp, D. H., Thornquist, M., Dandliker, P. S., Vicary, C. A., Flournoy, N., Kirk, L. E., Kersey, J. H. and Thomas, E. D. (1988): Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med., 318, 70-75.
3. Schimidt, G. M., Horak, D. A., Niland, J. C., Duncan, S. R., Forman, S. J. and Zaia, J. A. (1991): A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipient of allogeneic bone marrow transplants: the city of Hope-Stanford-Syntex CMV Study Group. N. Engl. J. Med., 324, 1005-1011.
4. Li, C. R., Greenberg, P. R., Gilbert, M. J., Goodrich, J. M. and Riddell, S. R. (1994): Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplantation: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood, 83, 1971-1979.
5. Boeckh, M., Gooley, T. A., Myerson, D., Cunningham, T., Schoch, G. and Bowden, R. A. (1996): Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88, 4063-4071.
6. Nguyen, Q., Champlin, R., Giralt, S., Rolston, K., Raad, I., Jacobson, K., Ippoliti, C., Hecht, D., Tarrand, J., Luna, M. and Whimbey, E. (1999): Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin. Infect. Dis., 28, 618-623.
7. Machado, C. M., Menezes, R. X., Macedo, M. C., Mendes, A. V, Boas, L. S., Castelli, J. S., Dulley, F. L. and Pannuti, J. S. (2001): Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant., 28, 1053-1059.
8. Prentice, H. G., Gluckman, E., Powles, R., Ljungman, P., Milpied, P., Fernandez-Ranada, J. M., Mandelli, F., Kho, P., Kennedy, L. and Bell, A. R. (1994): For the European Acyclovir for CMV Prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet, 343, 749-753.
9. Prentice, H. G., Gluckman, E., Powles, R., Ljungman, P., Milpied, P., Camara, R., Mandelli, F., Kho, P., Kennedy, L. and Bell, A. R. (1997): Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant., 19, 129-133.
10. Nakamura, R., Cortez, K., Solomon, S., Battiwalla, M., Gill, V J., Hensel, N., Childs, R. and Barrett, A. J. (2002): High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant., 30, 235-242.
11. Hazar, V., Kansoy, S., Kupesiz, A., Aksoylar, S., Kantar, M. and Yesilipek, A. (2004): High-dose acyclovir and preemptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplant., 33, 931-935.
12. Osarogiagbon, R. U., Defor, T. E., Weisdorf, M. A., Erice, A. and Weisdorf, D. J. (2000): CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol. Blood Marrow Transplant., 6, 280-288.
13. Kanda, Y., Mineishi, S., Saito, T., Seo, S., Saito, A., Suenaga, K., Ohnishi, M., Niiya, H., Nakai, K., Takeuchi, T., Kawahigashi, N., Shoji, N., Ogasawara, T., Tanosaki, R., Kobayashi, Y, Tobinai, K., Kami, M., Mori, S., Suzuki, R., Kunitoh, H. and Takaue, Y. (2001): Preemptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant., 27, 437-444.
14. Yanada, M., Yamamoto, K., Emi, N., Naoe, T., Suzuki, R., Taji, H., Iida, H., Shimokawa, T., Kohno, A., Mizuta, S., Maruyama, F., Wakita, A., Kitaori, K., Yano, K., Hamaguchi, M., Hamajima, N., Morishima, Y., Kodera, Y., Sao, H. and Morishita, Y. (2003): Cytomegalovirus antigenemia and outcome of patients treated with preemptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant., 32, 801-807.
15. Boeckh, M., Bowden, R. A., Gooley, T., Myerson, D., Corey, L., et al. (1999): Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood, 93, 1781-1782.
16. De la Camara, R. and Fernandez-Ranada, J. M. (1999): Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir? J. Infect. Dis., 180, 571-574.
17. Verma, A., Devine, S., Morrow, M., Chen, Y. H., Mihalov, M., Peace, D., Stock, W., Pursell, K., Wickrema, A., Yassine, M., Jessop, E. and van Besien, K. (2003): Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant., 31, 813-816.
18. Burns, L. J., Miller, W., Kandaswamy, C., DeFor, T. E., MacMilla, M. L., Van Burik, J. A. and Weisdorf, D. J. (2002): Randomized clinical trial of ganciclovir vs. acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant., 30, 945-951.
19. Heagy, W., Crumpacker, C., Lopez, P. A. and Finberg, R. W. (1991): Inhibition of immune functions by anti-viral drugs. J. Clin. Invest., 87, 1916-1924.
20. De Miranda, P. and Blum, M. R. (1983): Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother., 12, Suppl. B, 29-37.
21. Weller, S., Blum, M. R., Doucette, M., Burnette, T., Cederberg, D. M., de Miranda, P. and Smiley, M. L. (1993): Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther., 54, 595-605.
22. Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C. A., Crisp, A., Webster, A. and the Valacyclovir International Bone Marrow Transplant Study Group (2002): Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood, 99, 3050-3056.
23. Kruger, W. H., Bohlius, J., Cornely, O. A., Einsele, H., Hebart, H., Massenkeil, G., Schuttrumpf, S., Silling, G., Ullmann, A. J., Waldschmidt, D. T. and Wolf, H. H. (2005): Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann. Oncol., 16, 1381-1390.
24. Ottinger, H. D., Beelen, D. W., Schaefer, U. W. and Grosse-Wilde H. (1996): Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood, 7, 2775-2779.
25. Trenschel, R., Bernier, M., Delforge, A., Massy, M., Lebeau De Hemricourt, E., Maerevoet, M., Badjou, R., Stryckmans, P. and Bron, D. (1998): Myeloid and lymphoid recovery following bone marrow transplantation: a comparative study between related, unrelated bone marrow and allogeneic stem cell transplantation. Leuk. Lymphoma, 30, 325-352.
26. Trenschel, R., Ross, S., Husing, J., Ottinger, H., Elmaagacli, A., Roggendorf, M., Schaefer, U. W. and Runde, V. (2000): Reduced risk of persisting cytomegalovirus pp65 antigenmia, and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant., 25, 665-672.
27. Kroger, N., Zabelina, T., Kruger, W., Renges, H., Stute, N., Schrum, J., Kabisch, H., Schafhausen, P., Jaburg, N., Loliger, C., Schafer, P., Hinke, A. and Zander, A. R. (2001): Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br. J. Haematol., 113, 1060-1071.
28. Kuriyama, K., Todo, S., Ikushima, S., Fujii, N., Yoshihara, T., Tsunamoto, K., Naya, M., Hojo, M., Hibi, S., Morimoto, A. and Imashuku, S. (2001): Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia. Int. J. Hematol., 74, 455-460.
29. Nakai, K., Kanda, Y., Mineishi, S., Saito, T., Ohnishi, M., Niiya, H., Chizuka, A., Takeuchi, T., Matsubara, H., Kami, M., Makimoto, A., Tanosaki, R., Kunitoh, H., Tobinai, K. and Takaue, Y. (2002): Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant., 29, 237-41.
30. Junghanss, C., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Chauncey, T., McSweeney, P. A., Little, M. T., Corey, L. and Storb, R. (2002): Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 99, 1978-1985.
31. Busca, A., Locatelli, E, Barbui, A., Ghisetti, V, Cirillo, D., Serra, R., Audisio, E. and Falda, M. (2003): Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis., 5, 132-139.
32. Daly, A., McAfee, S., Dey, B., Colby, C., Schulte, L., Yeap, B., Sackstein, R, Tarbell, N. J., Sachs, D., Sykes, M. and Spitzer, T. R. (2003): Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol. Blood Marrow Transplant., 9, 373-382.